BiotechTube

PA21 + Sevelamer hydrochloride

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemodialysis

Conditions

Hemodialysis, Hyperphosphatemia

Trial Timeline

Apr 23, 2013 → Dec 10, 2013

NCT ID
NCT01850602

About PA21 + Sevelamer hydrochloride

PA21 + Sevelamer hydrochloride is a phase 3 stage product being developed by Kissei Pharmaceutical for Hemodialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT01850602. Target conditions include Hemodialysis, Hyperphosphatemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01850602Phase 3Completed

Competing Products

20 competing products in Hemodialysis

See all competitors
ProductCompanyStageHype Score
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744Chugai PharmaceuticalPhase 3
77
roxadustatAstellas PharmaPhase 3
77
ASP7991Astellas PharmaPhase 1
33
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
ASP1585Astellas PharmaPhase 2
52
Kiklin capsulesAstellas PharmaPre-clinical
23
DoravirineMerckApproved
85
BPS804 + PlaceboNovartisPhase 2
52
PA21 + PA21 + PA21 + PA21 + PlaceboKissei PharmaceuticalPhase 2
51
PA21Kissei PharmaceuticalPhase 3
76
PA21Kissei PharmaceuticalPhase 3
76
[¹⁴C]EtelcalcetideAmgenPhase 1
32
Epoetin HospiraPfizerPhase 3
76
Epoetin HospiraPfizerPhase 3
76
sodium thiosulfateSanofiPre-clinical
22
EnoxaparineSanofiApproved
84
Alirocumab 150 MG/ML [Praluent]Regeneron PharmaceuticalsPhase 3
76

Other Products from Kissei Pharmaceutical

KAD-1229 + Placebo + InsulinApproved
84
Avacopan, prednisolone and rituximab + Prednisolone and rituximabApproved
84
KLH-2109 + LeuprorelinPhase 3
76
KAD-1229Phase 3
76
KUC-7483 + Placebo + TolterodinePhase 3
76